29 October 2020
Visiongain has published a new report on Clinical Trial Supplies Market Report : Forecasts by Products & Services (Manufacturing, Packaging, Logistics, Distribution and Storage), Phases (l, ll, lll, lV), Drug Type (Small Molecule, Biologics), Therapeutic Areas (Oncology, Blood Disorders. PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Depending on the products and service, the market is bifurcated into Manufacturing, Packaging, Logistics, Distribution, and Storage. The logistic service sector is expected to be on top on the market due to the globalisation of clinical trials and increase in number of clinical trials including temperature sensitive products. And the comparator sourcing service segment is expected to grow at the highest CAGR during the forecast period.
North America is the largest regional market for clinical trial supplies, and this trend is anticipated to continue during the forecast period of 2020 to 2025. The presence of well-established CROs (Contract research organization) and the high and growing investments in R&D by pharmaceutical and biopharmaceutical companies are the major factors responsible for the large share of North America in the global clinical trial supplies market. Conversely, owing to the existence of a larger patient population and less-strict patient staffing regulations, the Asia Pacific market is expected to grow at the highest CAGR during the analysis period.
COVID-19 Impact on Clinical trial supplies Market
By the impact of COVID19 the clinical trial supply industry have a challenge to keep their trials in continuation. It is very important to distribute drug product among different regions and receive biological trials and transfer those samples to central labs, because of this pandemic the market is moving again in decentralised model of conducting clinical trials for result in high recovery rate of covid19 patients. Due to restriction on logistic industry it is very important to understand to manage clinical trials.
Clinical phase insights- phase 1 is expected to grow faster due to increase in number of outsourced phase 1 trials. Outsourcing is increasing because of lesser population sample and higher capital investment.
End use insights- biologics is expected to grow faster based on end use while pharmaceutical is expected to grow faster in forecast period.
Opportunity 1- due to the presence of well-established CROs and growing investment in R&D by pharmaceutical and biopharmaceutical companies the demand in clinical trials is increased.
Opportunity 2- due to COVID19 pandemic the pharma companies is outsourcing the trails for better medicine and in search for launching the vaccines.
- CROs are witnessing strong growth in the global clinical trial material and supplies market
- Clinical trial materials and supplies market is becoming more and more fragmented and expected to experience huge changes in terms of competition
- Recent partnership acquisition and expansion have taken place in the global clinical trial market and supplies market.
- Major players in the market include: Alamc Group (UK), Catalent, Inc. (US), PCI Services (US), Parexel International Corporation (US), Sharp Packaging Services (US), Biocair (UK), O&M Movianto (US), KLIFO A/S (Denmark), Thermo Fisher Scientific, Inc. (US), Capsugel (Switzerland), UDG Healthcare Plc. (Ireland), Bilcare Limited (India), Infosys (India), PRA Health Sciences, Inc. (US), Eurofins Scientific (Luxembourg), Marken (US), Seveillar Clinical Trial Supplies Pvt. Ltd. (India), and N-SIDE (Belgium).
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.